{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:21:20Z","timestamp":1765354880825,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen-Cilag, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41375-022-01629-7","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T11:04:00Z","timestamp":1656155040000},"page":"2125-2128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-4603","authenticated-orcid":false,"given":"Julia","family":"von Tresckow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Robrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Langerbeins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Othman","family":"Al-Sawaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-0140","authenticated-orcid":false,"given":"Moritz","family":"F\u00fcrstenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Illmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Klaproth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Tausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Anton","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-761X","authenticated-orcid":false,"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara F.","family":"Eichhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"1629_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fon-2017-0442","volume":"14","author":"P Cramer","year":"2018","unstructured":"Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018;14:499\u2013513.","journal-title":"Future Oncol"},{"key":"1629_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/asheducation-2013.1.138","volume":"2013","author":"M Hallek","year":"2013","unstructured":"Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematol Am Soc Hematol Educ Program. 2013;2013:138\u201350.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1629_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41375-018-0313-8","volume":"33","author":"J von Tresckow","year":"2019","unstructured":"von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33:1161\u201372.","journal-title":"Leukemia"},{"key":"1629_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"1629_CR5","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl J Med. 2015;373:2425\u201337.","journal-title":"N. Engl J Med"},{"key":"1629_CR6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497\u2013506.","journal-title":"Blood"},{"key":"1629_CR7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N. Engl J Med. 2019;380:2225\u201336.","journal-title":"N. Engl J Med"},{"key":"1629_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl J Med. 2018;378:1107\u201320.","journal-title":"N. Engl J Med"},{"key":"1629_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43\u201356.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01629-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:11:33Z","timestamp":1659337893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01629-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01629-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JvT: honoraria (AbbVie, AstraZeneca, Janssen, Roche); research funding (Janssen, Roche); PC: consulting fees (AbbVie, Acerta, AstraZeneca), honoraria (AbbVie, AstraZeneca, Janssen, Roche), travel support (AbbVie, AstraZeneca, Gilead, Janssen, Roche), research support (AbbVie, AstraZeneca, BeiGene, Gilead, Janssen, Novartis\/GSK, Roche); SR: nothing to disclose; PL: research funding (Janssen-Cilag), Consulting fees (Janssen-Cilag, AbbVie, Astra Zeneca), honoraria (Janssen-Cilag, AbbVie, Astra Zeneca), travel support (Janssen-Cilag, AbbVie, Astra Zeneca); AMF: Celgene (Research grant), AbbVie (Travel Support), Janssen (Advisory Board); OAS: Janssen (Personal fees, honoraria, research funding), Roche (Personal fees, honoraria, research funding), AbbVie (Personal fees, honoraria, research funding), BeiGene (Honoraria, research funding), AstraZeneca (Personal fees, honoraria), Gilead (Personal fees, honoraria); MF: nothing to disclose; TI: nothing to disclose; HK: nothing to disclose; ET: Consulting fees (Roche, Abbvie, Janssen), honoraria (Roche, Abbvie, Janssen), payment for expert testimony (Roche, Abbvie, Janssen), travel support (Janssen, AbbVie); MR: personal fees from Hoffman-La Roche (advisory board) and nonfinancial support from Celgene; KF: Honoraria (AbbVie, Roche), travel grants (Roche); CMW: Grants (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), consulting fees (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), honoraria (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), travel support (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), Participation on a Data Safety Monitoring Board or Advisory Board (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca); KAK: Mundipharma, Roche, Janssen (Speaker\u2019s bureau, Honoraria, Resarch support, Consulting); SS: Advisory board honoraria (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Research support (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Travel support (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Speaker fees (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis); SB: Janssen (research support), honoraria (Roche, AbbVie, Norvatis, Becton Dickonson, Janssen, Astra Zeneca, Sanofi); BE: grants and personal fees (Janssen-Cilag, Roche, Abbvie and Gilead), personal fees (Novartis, Celgene, ArQule, AstraZeneca and Oxford Biomedica (UK)), grants (BeiGene); MH: personal fees and other (AbbVie, Celgene, Gilead Sciences, Janssen, Mundipharma, Pharmacyclics, Roche).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}